共 14 条
[1]
A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. Wang W,Boffa MB,Bjazar L,et al. Biological Chemistry . 1998
[2]
Thrombin-acitivatable fibrinolysis inhibitor(TAFI) deficiency is compatible with murine life. Mariko N,Zheng FY,Lei Z,et al. The Journal of Clinical Investigation . 2002
[3]
Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Silveira A,Schaffeman K,Goossens F,et al. Thrombosis and Haemostasis . 2000
[4]
Human procarboxypeptidase B: three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor. Barbosa Pereira PJ,Segura-Martin S,Oliva B,et al. Journal of Molecular Biology . 2002
[5]
Reduced activity of TAFI ( thrombin-activatable fibrinolysis inhibitor ) in acute promyelocytic leukaemia. Meijers JC,Oudi jk EJ,Mosnier LO,et al. British Journal of Haematology . 2000
[6]
Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms. Zhao L,Morser J,Bajzar L,et al. Thrombosis and Haemostasis . 1998
[7]
Plasma TAFI antigen variations in healthy subjects. Chetaille P,Alessi MC,Kouassi D,et al. Thrombosis and Haemostasis . 2000
[8]
Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade,in human plasma. Schatteman KA,Gppssens FJ,Scharpe SS,et al. Clin Chim . 1999
[9]
Characterization of the gene encoding human TAFI. Boffa MB,Reid S,Joo E,et al. Biochemistry . 1999
[10]
CPR-Total(TAFI and activated TAFI) levels in plasma/serum of hemophiliacs. Guo X,Okada N,Okada H,et al. Microbiology and Immunology . 2000